(Q39042043)

8 September 2017

title

Targeting cisplatin-resistant human tumor cells with metabolic inhibitors (English)

1 reference

8 September 2017

Elizabeth J Sullivan

1 reference

8 September 2017

Metin Kurtoglu

1 reference

8 September 2017

Randall Brenneman

1 reference

8 September 2017

Huaping Liu

1 reference

8 September 2017

Theodore J Lampidis

1 reference

8 September 2017

publication date

19 December 2013

1 reference

Cancer Chemotherapy and Pharmacology

8 September 2017

published in

1 reference

8 September 2017

1 reference

8 September 2017

1 reference

8 September 2017

page(s)

417-427

1 reference

Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis.

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2366-8

Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2366-8

THE METABOLISM OF TUMORS IN THE BODY

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2366-8

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2366-8

Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2366-8

Targeting hypoxia, a novel treatment for advanced retinoblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2366-8

2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2366-8

Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2366-8

Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2366-8

Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2366-8

Multifaceted roles of glycolytic enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2366-8

Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2366-8

Functional organization of mammalian hexokinase II. Retention of catalytic and regulatory functions in both the NH2- and COOH-terminal halves

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2366-8

Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2366-8

SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2366-8

The relationship of thioredoxin-1 and cisplatin resistance: its impact on ROS and oxidative metabolism in lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2366-8

Thermal Stability of siRNA Modulates Aptamer- conjugated siRNA Inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2366-8

Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-d-glucose in tumor cells treated under hypoxic vs aerobic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2366-8

A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2366-8

Repeated cisplatin treatment can lead to a multiresistant tumor cell population with stem cell features and sensitivity to 3-bromopyruvate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2366-8

Retinoblastoma treatment: utilization of the glycolytic inhibitor, 2-deoxy-2-fluoro-D-glucose (2-FG), to target the chemoresistant hypoxic regions in LH(BETA)T(AG) retinal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2366-8

Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2366-8

10.1007/S00280-013-2366-8

21 January 2018

Identifiers

DOI

1 reference

8 September 2017

1 reference